Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Types of Conferences MSLs Attend & How To Prepare...
Summary
In this episode, George Lehman joins to discuss the strategic role of Medical Science Liaisons (MSLs) at conferences. The conversation covers the importance of conference attendance for professional development, the responsibilities MSLs hold, and effective networking strategies. George explains how MSLs decide which conferences to attend and emphasizes setting clear goals and deliverables. The episode also covers compliance in conference interactions, pre-conference planning, and best practices for post-conference follow-up. Balancing territory management with conference responsibilities is explored, concluding with final thoughts and a call to action for listeners to subscribe.
George Limen, Medical Liaison at Novo Nordisk discussed the types of conferences MSLs attend and how to prepare
George Shares….
π What are the types of conferences MSLs attend and why
π Who are the targets for MSLs and who do they meet
π What are the basic goals for MSLs to achieve at conferences
π How do MSLs plan for events and what is the follow up routine like
π Who covers the territory and how do you balance the effort when meetings happen
Medical Science Liaisons, conference strategies, networking for MSLs, MSL conference planning, post-conference follow-up
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary